Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05328908
Title	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)
Acronym	RELATIVITY-123
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	colorectal adenocarcinoma
Therapies	Regorafenib + Trifluridine-tipiracil hydrochloride Nivolumab and relatlimab-rmbw
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| POL \| NLD \| ITA \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS \| ARG